CRT Capital Initiates Ligand Pharmaceuticals With Buy

CRT Capital initiated coverage on Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) with a Buy rating.

The target price for Ligand Pharmaceuticals is set to $102.

Ligand Pharmaceuticals shares have dropped 13.54% over the past 52 weeks, while the S&P 500 index has surged 12.99% in the same period.

Ligand Pharmaceuticals' shares rose 4.99% to $66.75 in pre-market trading.